GST-pi expression in BCR-ABL+ and BCR-ABL- cells from CML patients

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Glutathione-sulfhydryl-transferase-pi (GST-pi) is implicated in cellular defense mechanisms.
• Previous observations suggested GST-pi expression during hematopoiesis in chronic myeloid leukemia (CML) patient samples.
• Understanding GST-pi's role in CML is crucial for disease monitoring.

Purpose of the Study:

• To confirm and quantify GST-pi expression in BCR-ABL positive and negative cells from CML patients.
• To investigate the correlation between GST-pi expression and different clinical statuses of CML.
• To evaluate the potential of GST-pi as a biomarker for minimal residual disease in CML.

Main Methods:

• Immunofluorescence staining was used to detect GST-pi expression.
• Fluorescence in situ hybridization (FISH) was employed to identify BCR-ABL positive and negative cells.
• Peripheral blood samples from 30 CML patients across various clinical stages (treatment, relapse, blastic crisis, post-transplant) and 30 healthy donors were analyzed.

Main Results:

• GST-pi was expressed in BCR-ABL positive cells, with expression levels increasing from treatment (1-67%) to blastic crisis (90-100%).
• GST-pi was also detected in some BCR-ABL negative cells, with varying percentages across clinical statuses.
• GST-pi was not expressed in peripheral blood cells of healthy donors.
• Complete absence of GST-pi expression in BCR-ABL positive cells was observed post-transplant (PT).

Conclusions:

• GST-pi expression is significantly elevated in malignant cells during active phases of CML.
• GST-pi expression patterns correlate with CML progression and response to treatment.
• GST-pi shows promise as a valuable biomarker for assessing minimal residual disease in CML patients.